This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749–1755.
Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82: 759–765.
Buttgereit F, Burmester GR, Brand MD . Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. Biochem Pharmacol 2000; 59: 597–603.
Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL et al. Methylprednisolone rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48: 2412–2417.
Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ . Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22: 2048–2053.
Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM . The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 2004; 63: 1079–1080.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099–4102.
Acknowledgements
Ofatumumab was made available by the GlaxoSmithKline special access program and Health Canada.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no conflict of interest.
Rights and permissions
About this article
Cite this article
Spaner, D. Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant Chronic Lymphocytic Leukemia. Leukemia 26, 1144–1145 (2012). https://doi.org/10.1038/leu.2011.329
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.329
This article is cited by
-
Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells
Leukemia (2019)
-
Role of bone marrow adipocytes in leukemia and chemotherapy challenges
Cellular and Molecular Life Sciences (2019)
-
The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia
Oncogene (2013)
-
A role for Danazol in chronic lymphocytic leukemia
Leukemia (2012)